{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:02Z","timestamp":1792088042552,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erdafitinib is approved for locally advanced\/metastatic urothelial cancer (LA\/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant but not specifically evaluated in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>UNITE is a multi-institutional retrospective study of patients with LA\/mUC treated with novel targeted agents. All patients with FGFR3 alterations treated with EV only, erdafitinib then EV (Erda-&amp;gt;EV), and EV then erdafitinib (EV-&amp;gt;Erda) were included. Sequential treatment with EV and Erda was not required. Primary endpoints were observed response rates (ORR) and progression-free survival (PFS); secondary endpoint was overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 83 patients with FGFR3 alterations and separated them into three cohorts: EV only (n\u2009=\u200944), Erda-&amp;gt;EV (n\u2009=\u200924), and EV-&amp;gt;Erda (n\u2009=\u200915). Most (72%) received \u22652 lines of therapy before erdafitinib (checkpoint inhibitor [87%], platinum-based chemotherapy [64%]). Median PFS with erdafitinib for EV-na\u00efve cohort was 7.5\u2009months and in EV-treated cohort 4.0\u2009months (HR 0.78; 95% CI 0.35-1.7). ORR with erdafitinib for EV-na\u00efve was 33% and EV-treated 31% (OR 1.1; 95% CI 0.29-4.1). Median PFS with EV for patients who were erdafitinib-na\u00efve was 6\u2009months and in erdafitinib-treated 5.3\u2009months (HR 0.61; 95% CI 0.34-1.09). ORR with EV was 54% in erdafitinib-na\u00efve cohort and 32% in erdafitinib-treated cohort (OR 2.5; 95% CI 0.87-6.3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with FGFR3-altered LA\/mUC, erdafitinib is active pre- and post-EV. Outcomes with erdafitinib were consistent with clinical trial data generated prior to broader frontline use of EV. Findings are hypothesis-generating and given small sample size should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf342","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T11:45:01Z","timestamp":1759664701000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of erdafitinib before or after enfortumab vedotin in\n                    <i>FGFR3<\/i>\n                    -altered advanced urothelial cancer: analysis of the UNITE collaborative study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-1875","authenticated-orcid":false,"given":"Cindy Y","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-5145","authenticated-orcid":false,"given":"Hyunsoo","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana Y","family":"Epstein","sequence":"additional","affiliation":[{"name":"Bladder Cancer Center, Dana Farber Cancer Center Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra Rafailia","family":"Bakaloudi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Washington, Fred Hutch Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafee","family":"Talukder","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Baylor College of Medicine , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison Carbone Cancer Center , Madison, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Jindal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, Helen Diller Cancer Center , San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Glover","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University , Stanford, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-4426","authenticated-orcid":false,"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University , Stanford, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology Oncology, University Hospital, Seidman Cancer Center, Case Western Reserve University , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope Comprehensive Cancer Center , Duarte, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Michigan Rogel Comprehensive Cancer Center , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-2280","authenticated-orcid":false,"given":"Nancy B","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Vanderbilt-Ingram Cancer Center , Nashville, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Mabey","sequence":"additional","affiliation":[{"name":"Divions of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Hoimes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Duke Cancer Institute , Durham, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T","family":"Evans","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Abuqayas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Iowa Holden Comprehensive Cancer Center , Iowa City, IA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lemke","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tsung","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Michigan Rogel Comprehensive Cancer Center , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Iowa Holden Comprehensive Cancer Center , Iowa City, IA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A","family":"Bilen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I","family":"Milowsky","sequence":"additional","affiliation":[{"name":"Divions of Oncology, University of North Carolina Lineberger Comprehensive Cancer Center , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit A","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University , Stanford, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison Carbone Cancer Center , Madison, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[{"name":"Bladder Cancer Center, Dana Farber Cancer Center Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai S","family":"Alva","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Michigan Rogel Comprehensive Cancer Center , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Washington, Fred Hutch Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S","family":"Koshkin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, Helen Diller Cancer Center , San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2025111120321071300_oyaf342-B1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B2","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B3","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025111120321071300_oyaf342-B4","doi-asserted-by":"publisher","first-page":"S1505","DOI":"10.1016\/j.annonc.2024.10.830","article-title":"LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): overall survival (OS) and safety analysis","volume":"35","author":"Grivas","year":"2024","journal-title":"Annals of Oncology"},{"key":"2025111120321071300_oyaf342-B5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2025111120321071300_oyaf342-B6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111120321071300_oyaf342-B7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025111120321071300_oyaf342-B8","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"2025111120321071300_oyaf342-B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2025111120321071300_oyaf342-B12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1200\/JCO.2025.43.5_suppl.770","article-title":"Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin\/pembrolizumab (EVP) in the evolving landscape of locally advanced\/metastatic (la\/m) urothelial cancer (UC)","volume":"43","author":"Chablani","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.euo.2021.10.006","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2025111120321071300_oyaf342-B14","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1200\/JCO.2023.41.16_suppl.4511","article-title":"Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: a phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)","volume":"41","author":"Grivas","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B15","doi-asserted-by":"publisher","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast growth factor receptor (FGFR) inhibitors in urothelial cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"key":"2025111120321071300_oyaf342-B16","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"2025111120321071300_oyaf342-B17","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025111120321071300_oyaf342-B18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"key":"2025111120321071300_oyaf342-B19","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1200\/JCO.2024.42.16_suppl.4578","article-title":"FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro)","volume":"42","author":"Siefker-Radtke","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B20","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1158\/1538-7445.am2023-4867","article-title":"Abstract 4867: effect of FGFR3 activity on nectin-4 expression in urothelial carcinoma","volume":"83","author":"Clark-Garvey","year":"2023","journal-title":"Cancer Res"},{"key":"2025111120321071300_oyaf342-B21","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025111120321071300_oyaf342-B22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025111120321071300_oyaf342-B23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025111120321071300_oyaf342-B24","doi-asserted-by":"publisher","first-page":"1151701","DOI":"10.3389\/fonc.2023.1151701","article-title":"Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis","volume":"13","author":"Rouvinov","year":"2023","journal-title":"Front Oncol"},{"key":"2025111120321071300_oyaf342-B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194891","article-title":"Targetable pathways in advanced bladder cancer: FGFR signaling","volume":"13","author":"Xiao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025111120321071300_oyaf342-B26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1541-7786.MCR-20-0751","article-title":"Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes","volume":"19","author":"Alhalabi","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2025111120321071300_oyaf342-B27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.euo.2024.12.006","article-title":"Genomic biomarkers associated with enfortumab vedotin outcomes for patients with advanced urothelial carcinoma: analysis of UNITE study data","volume":"8","author":"Jindal","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2025111120321071300_oyaf342-B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"2025111120321071300_oyaf342-B29","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): final results from the phase 2 norse study","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B30","doi-asserted-by":"publisher","first-page":"TPS595","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS595","article-title":"Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1\/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2\/3 genetic alterations (GAs)","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.2025.43.5_suppl.808","article-title":"ETCTN 10483: phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1\/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3\/2 genetic alterations (GAs)","volume":"43","author":"Jain","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B32","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2025111120321071300_oyaf342-B33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111120321071300_oyaf342-B34","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf342\/64539603\/oyaf342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf342\/64539603\/oyaf342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf342\/64539603\/oyaf342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:32:20Z","timestamp":1762911140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf342\/8277024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf342","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,7]]},"article-number":"oyaf342"}}